🇺🇸 FDA
Patent

US 11844841

Dosing regimens and related compositions and methods

granted A61KA61K38/00A61K47/60

Quick answer

US patent 11844841 (Dosing regimens and related compositions and methods) held by Apellis Pharmaceuticals, Inc. expires Mon Dec 14 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Apellis Pharmaceuticals, Inc.
Grant date
Tue Dec 19 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Dec 14 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
26
CPC classes
A61K, A61K38/00, A61K47/60, A61K47/643, A61K47/6901